[HTML][HTML] Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
…, R Lown, J Falconer, O Brake, J Batchelor, V Willimott… - Nature cancer, 2022 - nature.com
Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes
due to compromised immune responses, but the insights of these studies have been …
due to compromised immune responses, but the insights of these studies have been …
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
…, R McCulloch, M Bishton, A Beech, V Willimott… - Blood …, 2024 - ashpublications.org
During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England
for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. …
for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. …
[HTML][HTML] Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing
…, A Kelly, N Tipler, T Menne, MJ Ahearne, V Willimott… - The Lancet, 2023 - thelancet.com
People with blood cancers have an increased risk of severe COVID-19 disease despite booster
vaccine doses. 1 This group, like other disease groups at increased risk of severe COVID…
vaccine doses. 1 This group, like other disease groups at increased risk of severe COVID…
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies
…, R Lown, J Falconer, O Brake, J Batchelor, V Willimott… - medRxiv, 2021 - medrxiv.org
SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell
responses against the spike domain can be used to measure vaccine immune response. …
responses against the spike domain can be used to measure vaccine immune response. …
Multiple myeloma derived mitochondrial Damps induce inflammation in the bone marrow adipose tissue which promotes tumour development
Multiple myeloma (MM) is a malignancy of the antibody secreting plasma cells,
characterized by the localisation and accumulation of tumour cells in the bone marrow (BM) …
characterized by the localisation and accumulation of tumour cells in the bone marrow (BM) …
Myeloma Derived Mitochondrial Damage Associated Molecular Patterns Promote Pro-Tumoral Expansion By Inducing a Pro-Inflammatory Signature in the Bone …
A Jibril, JJ Mistry, JA Moore, C Hellmich, V Willimott… - Blood, 2020 - Elsevier
Multiple Myeloma (MM) is a malignancy of antibody producing B cells (plasma cells),
leading to the accumulation of tumour cells within the bone marrow (BM) microenvironment. …
leading to the accumulation of tumour cells within the bone marrow (BM) microenvironment. …
Multiple myeloma derived mitochondrial DAMPs induce a pro-inflammatory signature in the bone marrow microenvironment to promote pro-tumoral expansion
…, P Kumar, C Hellmich, JA Moore, JJ Mistry, V Willimott… - Cancer Research, 2021 - AACR
Multiple myeloma (MM) is an incurable malignancy of antibody (Ig) secreting differentiated B
cells (plasma cells) characterized by the accumulation and localization of tumor cells in the …
cells (plasma cells) characterized by the accumulation and localization of tumor cells in the …
[HTML][HTML] P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL …
…, A Santarsieri, R Mcculloch, M Bishton, V Willimott… - …, 2023 - journals.lww.com
Background: Ibrutinib (IBR) is an oral covalent Bruton’s kinase inhibitor licensed for treatment
of patients (pts) with relapsed/refractory mantle cell lymphoma (MCL). During the Covid-19 …
of patients (pts) with relapsed/refractory mantle cell lymphoma (MCL). During the Covid-19 …
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies (preprint)
…, R Lown, J Falconer, O Brake, J Batchelor, V Willimott… - 2021 - pesquisa.bvsalud.org
SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell
responses against the spike domain can be used to measure vaccine immune response. …
responses against the spike domain can be used to measure vaccine immune response. …
Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and-independent mechanisms in chronic lymphocytic leukemia
S Willimott, D Beck, MJ Ahearne, VC Adams… - Clinical Cancer …, 2013 - AACR
Purpose: The lymph node microenvironment promotes resistance to chemotherapy in chronic
lymphocytic leukemia (CLL), partly through induction of BCL2 family prosurvival proteins. …
lymphocytic leukemia (CLL), partly through induction of BCL2 family prosurvival proteins. …
